Medical News Software

Download | Private Label | Advertisers  

 

 

 
Pharmacy News

Featured Pharmacy Job

Virginia Manager, Pharmacy Operations LHS111408 - Metro DC - $ 90 to $ 140 K (per year) + Excellent Benefits, Relocation + Excellent Benefits, Relocation
Tue, 18 Nov 2008 14:22:00 GMT
The Manager of Operations of the Department of Pharmacy Services will assist the Director in all aspects of the day to day operations of the department to ensure the timely and accurate delivery of me...


Metabolex Announces Positive Results From Phase 2 Clinical Trial Of MBX-8025
Wed, 19 Nov 2008 00:00:00 PST
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 2 clinical trial of MBX-8025. A summary of the results was presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) on November 1, 2008. MBX-8025 is an oral drug candidate that is being evaluated for the treatment of dyslipidemia.

XTL Biopharmaceuticals Announces Top-Line Results From The Bicifadine Phase 2b Study For Diabetic Neuropathic Pain
Wed, 19 Nov 2008 00:00:00 PST
XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced the top-line results from the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain. The trial's primary objective was to compare the efficacy of two doses of Bicifadine against placebo in reducing pain associated with diabetic neuropathy. The primary endpoint of the study was the reduction in pain score during the course of treatment.

Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir Vs. Lopinavir/ritonavir As Part Of HIV Combination Therapy In Treatment-Experienced Adults
Wed, 19 Nov 2008 00:00:00 PST
Tibotec recently announced long-term study results from a phase 3 clinical trial, which compared PREZISTA(R) (darunavir)/ritonavir to lopinavir/ritonavir, as part of HIV combination therapy, in lopinavir/r-naive, treatment-experienced HIV-1 infected adults. A 96-week resistance analysis from the study, known as TITAN, was presented in an oral presentation at the Ninth International Congress on Drug Therapy in HIV Infection (HIV9) in Glasgow, UK on November 13, 2008.

Chronic Plaque Psoriasis - 2nd Case Of Progressive Multifocal Leukoencephalopathy In A Raptiva Patient
Tue, 18 Nov 2008 09:00:00 PST
Genentech, Inc. (NYSE:DNA) announced today that the company has issued a Dear Healthcare Provider letter to inform dermatologists and neurologists of a 2nd case of progressive multifocal leukoencephalopathy (PML) which resulted in the death of a 73-year old woman who had received Raptiva® (efalizumab) for approximately four years for treatment of chronic plaque psoriasis.

Cyclosporin Human Neuroprotection Validated By Maas Biolab Scientists
Tue, 18 Nov 2008 09:00:00 PST
Maas Biolab researchers CSO Eskil Elmér, M.D., Ph.D. and neuroscientist Magnus Hansson, M.D., Ph.D., and colleagues have for the first time ever demonstrated the mitochondrial permeability transition (mPT) or "megapore" occurs in viable adult human neuron mitochondria and the ability of cyclosporin-A to block its formation. These effects had previously been well characterized in animal neuroprotection studies and have now been validated in human brain tissue.

8,000 Pharmaceutical Scientists To Gather In Atlanta For The American Association Of Pharmaceutical Scientists' Annual Meeting And Exposition
Tue, 18 Nov 2008 09:00:00 PST
On November 16-20, 2008, 8,000 of the world's most prominent pharmaceutical scientists will put their best research on paper and present their findings at the AAPS Annual Meeting and Exposition. This year's meeting will take place in Atlanta at the Georgia World Congress Center.

Pharmacy News



Home | Download |About Us | Advertisers Partners | Private Label | Contact Us | Site Map | Help
MedReader.Com © | Privacy Policy | Terms of Use